EMA validates application for Opdivo + Yervoy for MSI-H/dMMR mCRC

CRUK and partners pledge £5.5m funding for colorectal cancer research

Cancer Research UK and partners on March 31 committed £5.5 million in funding to form a research team tasked with making personalized medicine a reality for people with colorectal cancer. The initiative is designed to unite research expertise and solve unanswered questions about the disease.

April 04, 2025

Vol.51 No.13

Drugs & Targets

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Exact Sciences Corp. announced the launch of Cologuard Plus, the most accurate noninvasive colorectal cancer screening test reported in studies to date. FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

Two recent studies by researchers from Regenstrief Institute and the Indiana University School of Medicine explore the effect of the pandemic on colorectal cancer screening tests and diagnostic colonoscopies in central Indiana.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Self-driving microscope solves previous challenges in microscopy

UT Southwestern Medical Center researchers developed a “self-driving” microscope that solves two challenges that have long plagued microscopy: 1) imaging living cells or organisms at dramatically different scales, and 2) following a specific structure or area of interest over long periods of time.

March 14, 2025

Vol.51 No.10

Drugs & Targets

EC approves Opdivo + Yervoy as first-line treatment for HCC

The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

March 14, 2025

Vol.51 No.10

Drugs & Targets

FDA accepts sBLA for Opdivo + Yervoy in CRC

FDA accepted Bristol Myers Squibb’s supplemental biologics license application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

February 28, 2025

Vol.51 No.08

EMA validates application for Opdivo + Yervoy for MSI-H/dMMR mCRC

YOU MAY BE INTERESTED IN

CRUK and partners pledge £5.5m funding for colorectal cancer research

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

Self-driving microscope solves previous challenges in microscopy

EC approves Opdivo + Yervoy as first-line treatment for HCC

FDA accepts sBLA for Opdivo + Yervoy in CRC

Never miss an issue!